|
|
Post by mnholdem on Sept 19, 2019 18:36:08 GMT -5
Overly optimistic? Don't sweat it, pal. Most of us have been there at one time or another.  |
|
|
|
Post by mnholdem on Sept 19, 2019 16:51:22 GMT -5
I see this as a huge positive. We've been waiting for more publications like this. Well, some of us have. Looks like the usual Debbie Downers have taken their usual negative stance. Bring on Europe! Woot woot! I suppose I am a Debbie Downer for remarking that the market evidently doesn't care about this huge positive news? Personally, I think some are reading way too much into a conference presentation. Just because a presentation is in a location, doesn't mean a launch in that location is at all imminent. (I've presented my work at conferences in Spain on several occasions, yet I've never moved to, or done business, there.) IMO, the Lung Safety presentation Dr. Kendall gave to the EASD last year was top-notch. Nothing happened in the year since. MannKind may be planning an marketing application for Europe but there's little reason to think it will happen this year given the costs involved and no regional partner to pick up those costs. Frankly, I hope I'm wrong about the dearth of partnership interests coming from Europe. |
|
|
|
Post by mnholdem on Sept 18, 2019 7:18:36 GMT -5
I remember reading quite a bit about that group. European-based, as I recall. The issue with them was that they appeared to be having difficulty getting funded. Although collaborations are a good thing, having a partner that can bankroll product development is preferable, IMO.  |
|
|
|
Post by mnholdem on Sept 18, 2019 4:17:32 GMT -5
|
|
|
|
Post by mnholdem on Sept 18, 2019 4:03:52 GMT -5
It appears that the patent registration in Europe for the collaboration between MannKind and Torrey Pines for pain management was withdrawn last month. The decision was published in March 2019 and the IPO database was updated yesterday Sept 17. register.epo.org/application?number=EP12784825&tab=mainExcerpt; EP2776053 - METHODS AND COMPOSITIONS FOR TREATING PAIN [Right-click to bookmark this link] Status The application is deemed to be withdrawn Status updated on 08.02.2019 Database last updated on 17.09.2019 Most recent event Application deemed to be withdrawn. Published on 13.03.2019 [2019/11] |
|
|
|
Post by mnholdem on Sept 17, 2019 4:17:17 GMT -5
Excerpt:
By connecting to One Drop, Afrezza users will be able to take advantage of the platform’s AI-enabled glucose forecasts and one-on-one connections to certified diabetes educators, among other features.
“Earlier this year, One Drop announced clinical data that demonstrated using Afrezza with One Drop provided a significant improvement in A1C levels,” says MannKind CEO Michael Castagna, explaining the partnership. “We believe the future of diabetes management will increasingly depend on data collected on a smartphone that provides real-time decision support insights.”
|
|
|
|
Post by mnholdem on Sept 16, 2019 16:03:02 GMT -5
Both MannKind and United touted the safety benefits of TrepT, particularly that the Phase 2 test results demonstrated that a larger dose of Treprostinil could be administered via the MannKind delivery mechanism. This equates to less daily doses and less hassle, including not having to regularly clean equipment.
|
|
|
|
Volume Six
Sept 16, 2019 13:31:21 GMT -5
via mobile
Post by mnholdem on Sept 16, 2019 13:31:21 GMT -5
If I split my screen I can keep my ticker at the top. Necessity is the mother of invention. |
|
|
|
Post by mnholdem on Sept 15, 2019 19:11:54 GMT -5
Bavarian you have been on this forum less than 8 weeks. I looked at your post history. You have 35 total post the last 13 (which is all I looked at) undermining or critical of VDEX post, THFM movement or Kovacocy. You obviously have an agenda your post are useless. You have not added one bit of useful commentary or information here. Yes, and proudly. Go look at other's posts too though, like Sportsrancho and several others. Call me out for an agenda? What of theirs? Are you saying that pro-HFM, pro-VDEX (as they relate to HFM), and pro-Kovacocy posts by HFM members provide usefulness and value to the forum and those that are against do not? Is this a forum then reserved for only HFM, anti-CEO shareholders of Mannkind? So it's okay that HFM has obfuscated this forum, and longs that are against this movement should shut up and go elsewhere? Bavarian, Quite some time ago the ProBoards staff consolidated multiple posts about VDex into its own thread and the same action was taken with HFM posts. While there is occasionally some “leakage” of these topics onto other threads, for the most part, VDex and HFM posts have been contained within their own threads. So your premise that VDex / HFM have taken over ProBoards-MNKD is a bit of an exaggeration. Each entity has its own potential impacts upon MannKind so the threads and posts contained within may be relevant to shareholders. Each shareholder may have his/her opinion and there has been differences of opinions among PB members, but it would have been inappropriate for forum staff to stifle these discussions. There are various topics covered within this forum and many contributions by multiple shareholders and non-shareholders. It’s certainly one of the most diverse and interesting stock discussion forums that I have encountered. |
|
|
|
Post by mnholdem on Sept 12, 2019 11:54:42 GMT -5
he’s been saying that ever since TrepT started. It’s very true. The cost for P1 depending on the drug is relatively inexpensive and success in P1 makes it much easier to find partners. He needs to show some results from those comments before I believe he is actually doing it. Mike said on a previous CC (either EPS or INV) they have the funds to bring all pipeline candidates to P1 phase status which takes about 2 years. He mentioned EPI is between Year 1 and 2 and they will be meeting with the FDA to get more guidance. |
|
|
|
Post by mnholdem on Sept 10, 2019 21:05:25 GMT -5
MannKind's IP includes a Technosphere Sumatriptan patent.
|
|
|
|
Post by mnholdem on Sept 10, 2019 20:56:18 GMT -5
|
|
|
|
Post by mnholdem on Sept 9, 2019 12:16:43 GMT -5
You bass players don’t have to read as many notes (LOL).
|
|
|
|
Post by mnholdem on Sept 9, 2019 4:33:04 GMT -5
BRIEF-Bioton Says Biomm Terminates Deal For Commercialization Of Recombinant Human Insulin In BrazilSept 9 (Reuters) - Bioton SA: * SAID ON SATURDAY THAT IT HAS RECEIVED FROM BRAZIL-BASED BIOMM A DECLARATION OF THE TERMINATION OF DEAL FOR THE COMMERCIALIZATION OF RECOMBINANT HUMAN INSULIN IN THE TERRITORY OF BRAZIL * THE MAIN REASON FOR TERMINATION INDICATED BY BIOMM WAS THE FAILURE TO SIGN THE AGREEMENT BETWEEN BIOMM AND THE MINISTRY OF HEALTH OF BRAZIL REGARDING THE SUPPLY INSULIN TO BRAZIL www.reuters.com/article/idUSL5N26014YSo, it appears that any conflict of interest between MannKind and Bioton is now gone and Biomm can focus its efforts on making Afrezza a success in Brazil.
|
|
|
|
Post by mnholdem on Sept 6, 2019 21:05:37 GMT -5
I think mytake’s is the one near the end by the construction sign.
|
|
